Cannabis Science Inc. Initiates Preclinical Investigation of CS-TATI-1 for European Studies for Squamous/Basal Cell Carcinomas and Kaposi's Sarcoma

Published: Sep 24, 2012

COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Cannabis Science (NASD OTC: CBIS), a pioneering U.S. Biotech Company developing pharmaceutical products for global public health challenges, is pleased to announce preclinical investigations being initiated in Europe for Squamous/Basal Cell carcinomas and Kaposi’s sarcoma based on inhibition of carcinogenicity utilizing cannabinoids that have been demonstrated in recent studies to significantly affect tumor necrosis.

Back to news